1. 62: A retrospective multicentre audit of outcome among patients with anaplastic lymphoma kinase (ALK) gene rearrangement positive non-small cell lung cancer (NSCLC) who have been treated with crizotinib in England. (January 2017) Authors: Yip, K.; Conibear, J.; Woolf, D.; Tarver, K.; Willis, B.; Hall, S.; Sun, F.; Kuhan, H.; Lambourne, B.; Piskilidis, P.; Kussaibati, R.; Martin, L.; Satar, N. Abdul; Gray, C.M.N.; Khan, A.; Doherty, G.; Prewett, S.; Smith, M.; Dancey, G.; Patterson, D.M. Journal: Lung cancer Issue: Volume 103(2017)Supplement 1 Page Start: S28 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A single centre experience of anti-PDL1 and anti-PD1 agents in treatment of non-small cell lung cancer (NSCLC). (January 2019) Authors: Saunders, E.; Rubasingham, J.; Muthukumar, D.; Ingle, C. Journal: Lung cancer Issue: Volume 127(2019)Supplement 1 Page Start: S44 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Audit of stage III non-small cell lung cancer (NSCLC) management in the Essex Cancer Network. (January 2019) Authors: Reinius, M.; Malek, A.; Powrie, D.; Yung, B.; Ingle, C.; Islam, M.R.; Dancey, G. Journal: Lung cancer Issue: Volume 127(2019)Supplement 1 Page Start: S8 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗